IL6 and chronic obstructive pulmonary disease: We completed a sensitivity analysis within our COPD group exploring the influence of ICS use and respiratory symptoms on nasal immune mediators and found lower IL‐6 and IL‐1β levels in our ICS group compared to those not utilizing ICS.